Expansion Therapeutics is a new 5AM Ventures company that is working to create cures for RNA diseases. There are certain illnesses called expansion disorders that are hereditary and do not respond to available medical treatments.
Tiny portions of DNA comprise the defective genes that create diseases like DM1. Such DNA repeating itself is the cause for RNA reproductions that accumulated and reach toxic levels within a person’s body. Learn more about Scott Rocklage: https://angel.co/scott-rocklage and https://scottrocklage.wordpress.com/
5AM Ventures began with $250 million in venture capital. The group raised the capital from a number of new, existing, institutional investors. Family offices, foundations, pension funds, and endowments are several funding sources. The 5AM Ventures team is also comprised of some extremely capable and qualified individuals.
These are individuals who can take a hands-on approach to matters and get things done. Their pedigree includes associations with technology companies, science company spin-outs, and companies developing cutting-edge therapeutics. Read more: Scott Rocklage | Bloomberg and Scott Rocklage | Crunchbase
Scott Rocklage, CEO of 5AM Ventures, is an active businessman who connects with a host of companies involved in the life sciences sector.
Dr. Rocklage joined the company in 2003. He currently has more than three decades of healthcare leadership and management experience. His efforts have resulted in three FDA drug application approvals. He has also entered a host of drugs into clinical trials.
His business background is impressive as well. He has served as CEO an President of Nycomed Salutar, Chairman and CEO of Cubist Pharmaceuticals, and Board Chairman of Relypsa to name several.
Rocklage graduated from the University of California, Berkeley with a degree in Chemistry. He received his PhD in Chemistry from MIT. At MIT, Rocklage conducted research in the famous lab of Richard R. Schrock.